Literature DB >> 21401500

Molecular biology of nucleoside transporters and their distributions and functions in the brain.

Fiona E Parkinson1, Vijaya L Damaraju, Kathryn Graham, Sylvia Y M Yao, Stephen A Baldwin, Carol E Cass, James D Young.   

Abstract

Pyrimidine and purine nucleosides and their derivatives have critical functions and pharmacological applications in the brain. Nucleosides and nucleobases are precursors of nucleotides, which serve as the energy-rich currency of intermediary metabolism and as precursors of nucleic acids. Nucleosides (e.g., adenosine) and nucleotides are key signaling molecules that modulate brain function through interaction with cell surface receptors. Brain pathologies involving nucleosides and their metabolites range from epilepsy to neurodegenerative disorders and psychiatric conditions to cerebrovascular ischemia. Nucleoside analogs are used clinically in the treatment of brain cancer and viral infections. Nucleosides are hydrophilic molecules, and transportability across cell membranes via specialized nucleoside transporter (NT) proteins is a critical determinant of their metabolism and, for nucleoside drugs, their pharmacologic actions. In mammals, there are two types of nucleoside transport process: bidirectional equilibrative processes driven by chemical gradients, and unidirectional concentrative processes driven by sodium (and proton) electrochemical gradients. In mammals, these processes, both of which are present in brain, are mediated by members of two structurally unrelated membrane protein families (ENT and CNT, respectively). In this Chapter, we review current knowledge of cellular, physiological, pathophysiological and therapeutic aspects of ENT and CNT distribution and function in the mammalian brain, including studies with NT inhibitors and new research involving NT knockout and transgenic mice. We also describe recent progress in functional and molecular studies of ENT and CNT proteins, and summarize emerging evidence of other transporter families with demonstrated or potential roles in the transport of nucleosides and their derivatives in the brain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21401500     DOI: 10.2174/156802611795347582

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  55 in total

1.  Expression of nucleoside transporter in freshly isolated neurons and astrocytes from mouse brain.

Authors:  B Li; L Gu; L Hertz; L Peng
Journal:  Neurochem Res       Date:  2013-09-12       Impact factor: 3.996

2.  Crithidia fasciculata adenosine transporter 1 (CfAT1), a novel high-affinity equilibrative nucleoside transporter specific for adenosine.

Authors:  Cassandra S Arendt
Journal:  Mol Biochem Parasitol       Date:  2013-10-10       Impact factor: 1.759

Review 3.  Equilibrative nucleoside transporters-A review.

Authors:  Rebba C Boswell-Casteel; Franklin A Hays
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2016-10-19       Impact factor: 1.381

Review 4.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

5.  Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency.

Authors:  Carlos Lopez-Gomez; Rebecca J Levy; Maria J Sanchez-Quintero; Martí Juanola-Falgarona; Emanuele Barca; Beatriz Garcia-Diaz; Saba Tadesse; Caterina Garone; Michio Hirano
Journal:  Ann Neurol       Date:  2017-05-04       Impact factor: 10.422

6.  Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors.

Authors:  Kazuya Tatani; Masahiro Hiratochi; Yoshinori Nonaka; Masayuki Isaji; Satoshi Shuto
Journal:  ACS Med Chem Lett       Date:  2015-01-28       Impact factor: 4.345

7.  Trypanosoma brucei thymidine kinase is tandem protein consisting of two homologous parts, which together enable efficient substrate binding.

Authors:  Farahnaz Ranjbarian; Munender Vodnala; Sharvani Munender Vodnala; Reza Rofougaran; Lars Thelander; Anders Hofer
Journal:  J Biol Chem       Date:  2012-03-21       Impact factor: 5.157

8.  Identification of the intracellular gate for a member of the equilibrative nucleoside transporter (ENT) family.

Authors:  Raquel Valdés; Johannes Elferich; Ujwal Shinde; Scott M Landfear
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

9.  ENT1 inhibition attenuates epileptic seizure severity via regulation of glutamatergic neurotransmission.

Authors:  Zucai Xu; Ping Xu; Yalan Chen; Jing Liu; Yanke Zhang; Yaodong Lv; Jing Luo; Min Fang; Jun Zhang; Jing Wang; Kewei Wang; Xuefeng Wang; Guojun Chen
Journal:  Neuromolecular Med       Date:  2014-12-10       Impact factor: 3.843

Review 10.  Regulation of adenosine levels during cerebral ischemia.

Authors:  Stephanie Chu; Wei Xiong; Dali Zhang; Hanifi Soylu; Chao Sun; Benedict C Albensi; Fiona E Parkinson
Journal:  Acta Pharmacol Sin       Date:  2012-10-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.